Literature DB >> 32700013

Premature rupture of the membranes at 16 weeks: report of a successful outcome of pregnancy and review of the literature.

Darko Tomica1, Mario Puljiz2, Luka Marcelić3, Damir Danolić2, Daniel Haubenberger1, Ilija Alvir2, Ivica Mamić2, Lucija Šušnjar2, Peter Diridl1.   

Abstract

Prelabor rupture of the fetal membranes (premature rupture of membranes, PROM) before or at the limit of fetal viability is condition associated with significant and serious pediatric morbidity and mortality. It is a rare problem, with an estimated incidence between 0.1 and 0.7%. Management of this condition is one of the most challenging clinical situations in obstetrics. We report the case of a pregnant woman presenting at 16 weeks gestation with ruptured membranes. The course of pregnancy was further complicated by complete placenta previa. Expectant management was undertaken, with term delivery and successful outcome of pregnancy. Expectant management is a reasonable approach in properly selected patients. Better understanding of the mechanisms of spontaneous membrane resealing is needed in order to improve poor outcomes. More published data and evidence are necessary to standardize treatment options for this rare condition.

Entities:  

Keywords:  AmniSure test; Complete placenta previa; Expectant management; Fetal viability; Premature rupture of membranes

Year:  2020        PMID: 32700013     DOI: 10.1007/s10354-020-00771-0

Source DB:  PubMed          Journal:  Wien Med Wochenschr        ISSN: 0043-5341


  2 in total

1.  Healing of Preterm Ruptured Fetal Membranes.

Authors:  Haruta Mogami; Annavarapu Hari Kishore; Yucel Akgul; R Ann Word
Journal:  Sci Rep       Date:  2017-10-13       Impact factor: 4.379

Review 2.  Meta-analysis of studies on biochemical marker tests for the diagnosis of premature rupture of membranes: comparison of performance indexes.

Authors:  Montse Palacio; Maritta Kühnert; Richard Berger; Cindy L Larios; Louis Marcellin
Journal:  BMC Pregnancy Childbirth       Date:  2014-05-31       Impact factor: 3.007

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.